New indications drive SGLT2 sales

Originally approved as diabetes therapies, SGLT2 inhibitors have experienced renewed growth with the addition of indications outside the condition in recent quarters. 

A case in point is Farxiga dapagliflozin from AstraZeneca plc (LSE:AZN; NASDAQ:AZN), which reported 2022 sales of nearly $4.4 billion for the therapy, a 56% increase at constant exchange rates over 2021. Much of that growth can be attributed to Farxiga’s expansion into new settings, with approval for heart failure with reduced ejection fraction in May 2020 and for chronic kidney disease patients a year later...